TabletsClinical Overview
Gefitinib Tablets (250mg) is an oral selective first-generation EGFR tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It competitively inhibits ATP binding at the tyrosine kinase catalytic domain of mutated EGFR (exon 19 deletion or exon 21 L858R substitution), arresting cell cycle progression and stimulating apoptosis in EGFR-addicted tumor cells. Indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have sensitizing EGFR mutations.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 250 mg once daily with or without food with a full glass of water. Swallow whole; can be dispersed in half a glass of drinking water (stir for ~10 minutes) and drunk immediately for patients with dysphagia.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Papulopustular acneiform rash, diarrhea, pruritus, dry skin, nausea, anorexia, elevated AST/ALT. Rare/Severe: Interstitial lung disease (ILD), corneal ulceration, and severe drug-induced liver injury.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Requires confirmation of EGFR mutation status prior to therapy initiation. Withhold treatment and evaluate immediately for interstitial lung disease if progressive dyspnea or cough occurs. Monitor liver enzymes periodically. Avoid concurrent PPI acid suppression therapy.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.